Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study.

Adverse events Allogeneic hematopoietic cell transplantation Related donors

Journal

Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629

Informations de publication

Date de publication:
04 2021
Historique:
received: 28 08 2020
revised: 05 01 2021
accepted: 11 01 2021
entrez: 10 4 2021
pubmed: 11 4 2021
medline: 3 7 2021
Statut: ppublish

Résumé

The incidence and risk factors for severe adverse events (SAEs) in related donors (RD) of hematopoietic cell transplants is unknown. The Related Donor Safe study is a prospective observational cohort of 1680 RDs and represents an opportunity to examine characteristics of SAEs in RDs. In this cohort, we found that SAEs were reported in a total 12 (0.71%) RDs. Of these, 5 SAEs occurred in bone marrow donors (5/404, 1.24%), and 7 (7/1276, 0.55%) were in donors of peripheral blood stem cells. All of the SAEs were considered to be related (definite, probable, or possible) to the donation process. There were no donor fatalities. Of the 12 RDs who experienced an SAE, 10 were either overweight or obese. Five of the 12 RDs had predonation medical conditions that would have resulted in either possible or definite ineligibility for donation were they being assessed as unrelated donors. These SAE data will be useful in the counseling of prospective RDs before planned donation and may be helpful in identifying donors who should be considered medically unsuitable for donation.

Identifiants

pubmed: 33836890
pii: S2666-6367(21)00010-5
doi: 10.1016/j.jtct.2021.01.009
pmc: PMC8036235
mid: NIHMS1666301
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

352.e1-352.e5

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL085707
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States

Informations de copyright

Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Références

Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182
pubmed: 32438042
Biol Blood Marrow Transplant. 2016 Mar;22(3):520-7
pubmed: 26597080
Bone Marrow Transplant. 2015 Feb;50(2):244-7
pubmed: 25387092
Biol Blood Marrow Transplant. 2015 Dec;21(12):2052-2060
pubmed: 26271194
Haematologica. 2019 Apr;104(4):844-854
pubmed: 30381298
Blood. 2014 Jun 5;123(23):3655-63
pubmed: 24735965
Blood Adv. 2020 Feb 25;4(4):706-716
pubmed: 32092138
Blood. 2010 Jun 17;115(24):5097-101
pubmed: 20228276
Bone Marrow Transplant. 2015 May;50(5):637-41
pubmed: 25730182
Biol Blood Marrow Transplant. 2019 Apr;25(4):699-711
pubmed: 30423480
Blood. 2013 Jan 3;121(1):197-206
pubmed: 23109243

Auteurs

Matthew D Seftel (MD)

University of British Columbia, Vancouver, British Columbia, Canada.

Pintip Chitphakdithai (P)

Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, Minnesota.

John P Miller (JP)

National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.

Hati Kobusingye (H)

Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, Minnesota.

Brent R Logan (BR)

Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.

Michael Linenberger (M)

Fred Hutchinson Cancer Research Center, Seattle, Washington.

Andrew S Artz (AS)

University of Chicago Hospitals, Chicago, Illinois.

Ann E Haight (AE)

Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia.

David A Jacobsohn (DA)

Children's National Medical Center, Washington, District of Columbia.

Mark R Litzow (MR)

Mayo Clinic Rochester, Rochester, Minnesota.

Margarida Magalhaes-Silverman (M)

University of Iowa Hospitals & Clinics, Iowa City, Iowa.

George B Selby (GB)

HCA Health Services of Oklahoma, Inc., University of Oklahoma, Oklahoma City, Oklahoma.

Madhuri Vusirikala (M)

University of Texas Southwestern Medical Center, Dallas, Texas.

Mary M Horowitz (MM)

Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.

Galen E Switzer (GE)

University of Pittsburgh, Pittsburgh, Pennsylvania.

Dennis L Confer (DL)

Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, Minnesota; National Marrow Donor Program/Be The Match, Minneapolis, Minnesota.

Bronwen E Shaw (BE)

Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: beshaw@mcw.edu.

Michael A Pulsipher (MA)

Children's Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH